While national authorities in 2016 and 2017 recommended and reimbursed men having sex with men below the age of 27, the research planned to study human papillomavirus (HPV) intake vaccines for French men comprehensively over a 4-year cycle related to those reforms. Data on the selling of vaccines to men from 2015 to 2018 by all French pharmacies in the national public insurance database was obtained. Data was graded based on the age of the patients and the time of dispensation in order to show aggregate adoption by age over time. To examine the effect of the refund, a time-series analysis was performed, and an exponential smoothing extrapolation was used. During the study time, 12,814 HPV vaccines were administered to men. The majority of cases had an average of 29.
The vaccine uptake was significant for men over 26, according to a vaccine age analysis. After the second quarter of 2017 there was an unprecedented growth in the number of vaccinations sold. While the study found signs of a marked rise in uptake over the most recent decade, HPV intake among the French men is partially misaligned with guidelines and repayment for the generation, and is overall still modest.